Candoo Pharmatech Company Inc.
Yongqiang Li, PhD has extensive work experience in the biopharmaceutical industry as well as in the field of education. Yongqiang is currently the CEO of Candoo Pharmatech Company Inc., where they established and leads a technology-driven biopharmaceutical company that provides CRDMO platform services. Yongqiang'srole involves accelerating product development and reducing new drug access costs. Prior to this, Yongqiang worked at Apotex Inc. as a Senior Scientific Leader and Scientific Leader. Yongqiang also served as a Scientist at the company. In addition, Yongqiang has experience in teaching and was a Course Instructor at the University of Toronto. Yongqiang also worked as a Part-time Faculty at Seneca College and a Teaching Assistant at the University of Toronto.
Yongqiang Li, PhD earned their Doctor of Philosophy (Ph.D.) in Pharmaceutics and Drug Delivery from the University of Toronto between 2003 and 2007. Prior to that, they completed a Master's degree in Pharmaceutical Science and Engineering and a Bachelor's degree in Pharmaceutical Science and Engineering from Sichuan University.
This person is not in any teams
Candoo Pharmatech Company Inc.
Candoo Pharmatech Company Inc. is a technology-driven, customer-centric pharmaceutical CDMO specializing in advanced formulation and manufacturing solutions to small and large molecules. Candoo believes an innovative, efficient and affordable drug delivery platform is pivotal to substantially reduce the cost of new drug access. We provide experienced, agile and cost-effective contract development and manufacturing services including pre-formulation, formulation, analytical, dissolution, manufacturing, regulatory submission, GastroPlus modeling and IVIVC, and toxicology evaluation for global pharmaceutical and biotech industries. We have proven track record of success to develop first-to-file products (Paragraph IV), achieve target drug absorption profile, pass bioequivalence studies right-first-time, and get FDA regulatory approval within one review cycle. Our expertise spans a broad spectrum of oral, topical and parenteral dosage forms in the fields of NDA, 505b(2) and generics (ANDA). We effectively support pharma, biotech and medical research institutions all over the world accelerate molecules to medicines with PBPK model-informed developability assessment, best fit formulation, scalable manufacturing process and faster turnaround time. Candoo was founded in 2018 and is a Canadian subsidiary of Crystal Pharmatech. As a member of Ontario Research Innovation & Commercialization Center, industrial partner of Canada Natural Sciences and Engineering Research Council (NSERC) CREATE Training Program for Controlled Release Leaders (ContRoL) and Mitacs Research and Development Program, Candoo has the state-of-the-art R&D and cGMP facilities of 12,500 square feet (cGMP facility under renovation), equipped with modern and cGMP-compliance equipment, and locates at the pharmaceutical business park in Mississauga, Ontario, the hub of pharmaceutical industry in Canada.